Sernova Receives US FDA IND Allowance to Initiate a US Clinical Trial of Its Cell Pouch for the Treatment of Type 1 Diabetes
Sernova Corp., a clinical stage company developing regenerative medicine technologies for the long-term treatment of diseases including diabetes and hemophilia, is pleased to announce it has received US Food and Drug Administration (FDA) notice of allowance for its IND for a new human clinical trial with the Cell Pouch System (TM) (CPS) in the United States.
View full press release